ATE455103T1 - Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate - Google Patents

Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate

Info

Publication number
ATE455103T1
ATE455103T1 AT06785361T AT06785361T ATE455103T1 AT E455103 T1 ATE455103 T1 AT E455103T1 AT 06785361 T AT06785361 T AT 06785361T AT 06785361 T AT06785361 T AT 06785361T AT E455103 T1 ATE455103 T1 AT E455103T1
Authority
AT
Austria
Prior art keywords
sup
phenylglycinamide
pyridylglycinamide
derivatives used
anticoagulation agents
Prior art date
Application number
AT06785361T
Other languages
English (en)
Inventor
Xiaojun Zhang
Alexandra A Nirschl
Yan Zou
Eldon Scott Priestley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE455103T1 publication Critical patent/ATE455103T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06785361T 2005-06-24 2006-06-22 Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate ATE455103T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69407605P 2005-06-24 2005-06-24
US69407405P 2005-06-24 2005-06-24
PCT/US2006/024345 WO2007002313A2 (en) 2005-06-24 2006-06-22 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants

Publications (1)

Publication Number Publication Date
ATE455103T1 true ATE455103T1 (de) 2010-01-15

Family

ID=37467511

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06785361T ATE455103T1 (de) 2005-06-24 2006-06-22 Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate

Country Status (6)

Country Link
US (1) US7456195B2 (de)
EP (1) EP1910298B1 (de)
AT (1) ATE455103T1 (de)
DE (1) DE602006011752D1 (de)
ES (1) ES2337831T3 (de)
WO (1) WO2007002313A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576098B2 (en) * 2004-12-08 2009-08-18 Bristol-Myers Squibb Company Heterocyclic compounds as inhibitors of factor VIIa
AR054321A1 (es) 2005-01-10 2007-06-20 Bristol Myers Squibb Co Derivados en fenilglicinamida utiles como anticoagulantes
TW200745062A (en) * 2005-12-23 2007-12-16 Bristol Myers Squibb Co Macrocyclic factor VIIA inhibitors useful as anticoagulants
EP2061756B1 (de) 2006-06-08 2013-09-25 Bristol-Myers Squibb Company 2-aminocarbonylphenylamino-2-phenylacetamide als faktor-viia-hemmer zur verwendung als antikoagulantien
JP2010513562A (ja) * 2006-12-20 2010-04-30 ブリストル−マイヤーズ スクイブ カンパニー 抗凝血剤として有用な二環状ラクタム第viia因子阻害剤
PE20081775A1 (es) * 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
EP2191887A1 (de) 2008-11-26 2010-06-02 Polymers CRC Limited Anklickbare Dünnschichtverbundpolyamidmembrane
EP2462123B1 (de) 2009-08-04 2013-10-02 Merck Sharp & Dohme Corp. 4,5,6-trisubstituierte pyrimidin- derivate als factor ixa inhibitoren
WO2011043359A1 (ja) 2009-10-06 2011-04-14 協和発酵キリン株式会社 芳香族複素環化合物を含有する医薬
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
WO2013184734A1 (en) 2012-06-08 2013-12-12 Bristol-Myers Squibb Company Macrocyclic factor viia inhibitors
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
TW201629026A (zh) 2015-02-02 2016-08-16 佛瑪治療公司 作為hdac抑制劑的3-烷基雙環[4,5,0]異羥肟酸
UY36548A (es) 2015-02-05 2016-06-01 Bayer Cropscience Ag Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas
TWI828952B (zh) 2015-06-05 2024-01-11 美商艾佛艾姆希公司 作為除草劑之嘧啶氧基苯衍生物
HK1252693A1 (zh) * 2015-06-30 2019-05-31 Dana Farber Cancer Institute, Inc. Egfr抑制剂及其使用方法
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
CN105481733A (zh) * 2015-12-30 2016-04-13 苏州诚和医药化学有限公司 一种一步法合成2-甲氧基-5-氨磺酰基苯甲酸甲酯的方法
HRP20220223T1 (hr) 2017-01-11 2022-04-29 Alkermes, Inc. Biciklički inhibitori histon deacetilaze
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
CN111606827B (zh) * 2020-06-23 2022-10-25 内蒙古京东药业有限公司 一种制备依度沙班手性胺中间体的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2667864B2 (fr) * 1990-03-07 1994-08-05 Rhone Poulenc Sante Derives de n-phenyl glycinamides, leur preparation et les medicaments les contenant.
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
SI0921116T1 (en) * 1997-12-04 2003-10-31 F. Hoffmann - La Roche Ag N-(4-carbamimido-phenyl)-glycine amide derivatives
AU2300699A (en) * 1998-02-17 1999-08-30 Ono Pharmaceutical Co. Ltd. Amidino derivatives and drugs containing the same as the active ingredient
CN1245381C (zh) * 1998-12-14 2006-03-15 弗·哈夫曼-拉罗切有限公司 苯基甘氨酸衍生物
IL144032A0 (en) * 1999-01-13 2002-04-21 Genentech Inc Serine protease inhibitors
EP1059302A1 (de) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Faktor VIIa Inhibitore
US6548694B2 (en) * 2000-05-23 2003-04-15 Hoffman-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
EP1332131A2 (de) * 2000-11-07 2003-08-06 Bristol-Myers Squibb Company Säurederivate und ihre verwendung als inhibitoren von serinproteasen
DE10102322A1 (de) * 2001-01-19 2002-07-25 Merck Patent Gmbh Phenylderivate
DE60139510D1 (de) * 2001-04-06 2009-09-17 Biocryst Pharm Inc Biarylverbindungen als serinproteaseinhibitoren
DE10139060A1 (de) * 2001-08-08 2003-02-20 Merck Patent Gmbh Phenylderivate
US6642386B2 (en) * 2002-02-06 2003-11-04 Hoffmann-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
US6821974B2 (en) * 2002-03-05 2004-11-23 Barbeau Pharma, Inc Stable pharmaceutical compositions
DE10214832A1 (de) * 2002-04-04 2003-10-16 Merck Patent Gmbh Phenylderivate 4
US7122559B2 (en) * 2003-02-11 2006-10-17 Bristol-Myers Squibb Company Phenylglycine derivatives useful as serine protease inhibitors
US7144895B2 (en) * 2003-02-11 2006-12-05 Bristol-Myers Squibb Co. Benzene acetamide compounds useful as serine protease inhibitors
US7576098B2 (en) * 2004-12-08 2009-08-18 Bristol-Myers Squibb Company Heterocyclic compounds as inhibitors of factor VIIa
AR054321A1 (es) * 2005-01-10 2007-06-20 Bristol Myers Squibb Co Derivados en fenilglicinamida utiles como anticoagulantes
BRPI0616865A2 (pt) * 2005-10-05 2011-07-05 Hoffmann La Roche compostos derivados de naftiridina, processo para preparação dos mesmos, medicamentos e uso dos mesmos
US7618985B2 (en) * 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives

Also Published As

Publication number Publication date
DE602006011752D1 (de) 2010-03-04
EP1910298A2 (de) 2008-04-16
EP1910298B1 (de) 2010-01-13
US20070003539A1 (en) 2007-01-04
WO2007002313A2 (en) 2007-01-04
WO2007002313A3 (en) 2007-05-18
ES2337831T3 (es) 2010-04-29
US7456195B2 (en) 2008-11-25

Similar Documents

Publication Publication Date Title
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
WO2008005368A3 (en) Piperazines as p2x7 antagonists
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
DE60225671D1 (de) Pharmazeutisch wirksame piperidinderivate
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
SE0400284D0 (sv) Novel compounds
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
ATE283253T1 (de) Substituierte aminopropoxyarylderivate als lxr agonisten
NO20082389L (no) 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
MX2009006689A (es) Inhibidores viia de los factores macrociclicos utiles como anticoagulantes.
ECSP055867A (es) Derivados de pirrolopirimidina
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
ES2571779T3 (es) Inhibidores de cinasa a base de nicotinamida
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
ES2422557T3 (es) Compuestos y composiciones como moduladores de la ruta Hedgehog
EA200900135A1 (ru) Производные пиразола в качестве ингибиторов цитохрома р450
NO20075734L (no) Tiofenforbindelser og trombopoietin reseptoractivatorer
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties